
Revolutionizing Autism Treatment: Oryzon’s Groundbreaking Study on Personalized Medicine for Phelan-McDermid Syndrome Patients
Oryzon Genomics Announces Publication of Final Results from Observational Study on Phelan-McDermid Syndrome On March 5, 2025, Oryzon Genomics, a clinical-stage biopharmaceutical company, made an exciting announcement regarding the publication of the final results of an observational clinical study on Phelan-McDermid syndrome (PMS). This condition, also known as 22q13.3 deletion syndrome, is a rare genetic…